Herpes-Block

Fever blisters / cold sores

A muco adhesive gel based on Hyaluronic Acid

adjuvant in the treatment of cold sores/fever blisters and other irritations of the buccal mucosa by acting on the symptoms and promoting an optimal skin-repair environment.

It takes advantage of the barrier effect of its mucus-adhesive matrix, isolating the injured part from mechanical and chemical stress (rubbing, saliva, drinks, etc.), reducing the pain, ensuring protection and encouraging natural healing.

The presence of a patented ingredient based on Shikimic acid  exerts a natural antimicrobial and antioxidant activity and keeps the microenvironment of the lesion under control respecting oral microbiota (selective antimicrobial action)

Regulatory status

Medical device class IIa

Indication

It can be used during the different stages of cold sores (herpes labialis) for the symptomatic treatment of manifestations.
Effective in the treatment of superficial cold sores (fever blisters) and other superficial irritations of the oral mucosa.

Ingredients

  • Hyaluronic acid: moisturizing agent, it maintains a correct tissue hydration playing an essential role in tissue repair processes.
  • Verochic: patented natural compound with antioxidant properties and able to keep the microenvironment of the lesion under control. It is able to inhibit the proliferation of pathogenic microorganisms without affecting the beneficial bacteria.
  • Aloe vera: with soothing and moisturizing properties.
  • Red Alga Gel: Pacific red algae extract able to restore skin natural water content by exerting a film-forming effect.

Application

Apply 1 or 2 drops of gel 2-4 times a day, completely covering the lesion.

Claims

  • With Verochic - patented antimicrobial agent
  • Barrier effect
  • High protection / shield effect
  • Rapid healing
  • Pain relief
  • Filming effect protecting from irritation
  • Targeted action
  • Intensive treatment

Efficacy tests

In-vitro tests

  • muco-adhesion properties: 65.7% after 60 minutes.
  • barrier effect: -35.9% IL-1α